Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment

Inclusion Criteria: Histologically confirmed* solid tumor, including any of the following: Ewing's sarcoma/peripheral primitive neuroectodermal tumor (PNET) Osteosarcoma Rhabdomyosarcoma Neuroblastoma High-grade astrocytoma Low-grade astrocytoma Glioblastoma multiforme Ependymoma Hepatoblastoma Germ cell tumors of any site Rare tumors of interest, including any of the following: Soft tissue sarcoma Hepatocellular carcinoma Childhood/adolescent colorectal carcinoma Childhood/adolescent renal cell carcinoma Childhood/adolescent adrenocortical carcinoma Childhood/adolescent nasopharyngeal carcinoma Recurrent disease OR refractory to conventional therapy Measurable disease by clinical exam, CT scan, MRI, or positron emission tomography Performance status - Karnofsky 50-100% (for patients over age 10) Performance status - Lansky 50-100% (for patients age 10 and under) At least 8 weeks Absolute neutrophil count ≥ 1,000/mm^3* Platelet count ≥ 75,000/mm^3* (transfusion independent) Hemoglobin ≥ 8.0 g/dL* (RBC transfusions allowed) Granulocytopenia, anemia, and/or thrombocytopenia due to bone marrow metastases or extensive prior radiotherapy allowed provided the above hematological criteria are met Bilirubin ≤ 3 mg/dL Creatinine based on age as follows: ≤ .8 mg/dL (for patients age 5 and under) ≤ 1.0 mg/dL (for patients age 6 to 10) ≤ 1.2 mg/dL (for patients age 11 to 15) ≤1.5 mg/dL (for patients age 16 to 21) Creatinine clearance or radioisotope glomerular filtration rate > 20 mL/min No uncontrolled seizure disorder No uncontrolled infection CNS toxicity ≤ grade 2 Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception Recovered from prior immunotherapy At least 7 days since prior anticancer biologic therapy More than 1 week since prior growth factors At least 6 months since prior allogeneic stem cell transplantation No evidence of active graft-vs-host disease No concurrent immunomodulating agents Recovered from prior chemotherapy No prior oxaliplatin Prior carboplatin or cisplatin allowed More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas) No other concurrent anticancer chemotherapy Concurrent dexamethasone for CNS tumors allowed provided patient has been on a stable or decreasing dose for ≥ 1 week before study entry Recovered from prior radiotherapy At least 2 weeks since prior local palliative radiotherapy (small port) At least 6 months since prior craniospinal radiotherapy At least 6 months since prior radiotherapy to ≥ 50% of the pelvis At least 6 weeks since other prior substantial radiotherapy to the bone marrow Concurrent radiotherapy to localized painful lesions allowed provided ≥ 1 measurable lesion is not irradiated No other concurrent investigational agents No other concurrent anticancer agents